SympSolutions provides a one-time, non-invasive treatment to millions of severely hypertension patients who currently have no other option
SympSolutions is developing the AccuRIGHT system which in a clinic treats millions of severely hypertensive patients who no longer respond to oral medications. These patients are extreme risk of strokes and heart diseases. The market for device-based treatment for hypertension is projected to be $6 billion by 2018. AccuRIGHT has a significant competitive advantage over other players because of it is non-invasive and cost-effective solution.